Erosive nappy erythema following sunitinib intake
Saoussane Kharmoum, Hassan Errihani
Corresponding author: Saoussane Kharmoum MD, Department of medical oncology, National institute of oncology, Rabat Morocco
Received: 26 Nov 2012 - Accepted: 29 Nov 2012 - Published: 01 Feb 2013
Domain: Clinical medicine
Keywords: Erosive, erythema, sunitinib, antiangiogenic drug
©Saoussane Kharmoum et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cite this article: Saoussane Kharmoum et al. Erosive nappy erythema following sunitinib intake. Pan African Medical Journal. 2013;14:46. [doi: 10.11604/pamj.2013.14.46.2235]
Available online at: https://www.panafrican-med-journal.com//content/article/14/46/full
Erosive nappy erythema following sunitinib intake
Saoussane Kharmoum1,&, Hassan Errihani1
1Department of medical oncology, National institute of oncology, Rabat Morocco
&Corresponding author
Saoussane Kharmoum MD, Department of medical oncology, National institute of oncology, Rabat Morocco
We report on the case of a 54 years old man treating for a metastatic renal carcinoma who had experienced a dermatological toxicity referring to sunitinb intake. The antiangiogenic drug was delivered at a daily dose of 50mg for 4 weeks followed by two weeks of rest. By the second week of treatment the patient presented a nappy erythema evolving towards erosive lesions bleeding at mild friction and extending to the perianal and scrotal area, the process fulfilled the maximal intensity at 4 weeks and improved after the discontinuation of sunitinib. The patient refused the reintroduction of the drug. No skin biopsy was developed seeing that the lesions disappeared 4 weeks later.
Figure 1: Erosive nappy erythema (A) and scrotal erythema (B)